Moroxydine

As a classic broad-spectrum antiviral drug, moroxydine inhibits the activities of viral DNA and RNA polymerases to block the viral reproductive cycle, and exerts inhibitory effects on a variety of respiratory viruses including influenza virus, parainfluenza virus, rhinovirus, coronavirus, adenovirus, etc. It is clinically mostly used for the prevention and treatment of viral diseases such as influenza, epidemic parotitis, chickenpox, herpangina, etc. Its applicable population covers adults and children, and it is very widely used in primary medical scenarios, being a common option for early intervention of viral infections.

At present, the domestic moroxydine market has entered a mature development stage, with an annual market size of approximately 230 million yuan, and the compound annual growth rate in the recent three years has maintained at around 1.2%. Due to its early launch and expired patent period, the market is dominated by generic drug supply. There are more than 30 domestic manufacturers, among which enterprises in North China and East China account for nearly 70% of the production capacity. As a Class B medical insurance drug, the winning bid price of moroxydine oral preparations in the provincial centralized procurement of multiple provinces is stable in the range of 0.05-0.12 yuan per tablet, with obvious cost-effectiveness advantages, and the demand from primary medical institutions accounts for more than 65% of the total market share.

The original research enterprise of moroxydine is Merck, Germany, which first developed and launched the product in the 1950s under the trade name "Virustat", and the core compound patents fully expired in the 1970s. At present, the mainstream dosage form in the domestic market is tablet, with the usual specification of 0.1g, and the relevant reference listed drug has been included in the FDA Orange Book. In terms of domestic API registration, nearly 15 enterprises have obtained CDE registration numbers (status A) for moroxydine APIs. The domestically approved preparations for marketing include multiple varieties such as moroxydine hydrochloride tablets and moroxydine hydrochloride injection, with sufficient supply. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for moroxydine API, most of which are in stock. Orders placed before 16:00 can be shipped on the same day. All reference standards meet the requirements of multiple regulations including the Chinese Pharmacopoeia and FDA, and can fully meet the full-process needs of pharmaceutical enterprises such as quality research, stability study, registration and declaration.